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Forward genetic screens with genome-wide CRISPR
libraries are powerful tools for resolving cellular cir-
cuits and signaling pathways. Applying this technol-
ogy to organoids, however, has been hampered
by technical limitations. Here we report improved
accuracy and robustness for pooled-library CRISPR
screens by capturing sgRNA integrations in single
organoids, substantially reducing required cell
numbers for genome-scale screening. We applied
our approach to wild-type and APC mutant human
intestinal organoids to identify genes involved in
resistance to TGF-b-mediated growth restriction, a
key process during colorectal cancer progression,
and validated hits including multiple subunits of the
tumor-suppressive SWI/SNF chromatin remodeling
complex. Mutations within these genes require con-
current inactivation of APC to promote TGF-b resis-
tance and attenuate TGF-b target gene transcription.
Our approach can be applied to a variety of assays
and organoid types to facilitate biological discovery
in primary 3D tissue models.
INTRODUCTION
Mutations that initiate transformation of intestinal stem cells
(ISCs) into cancer cells commonly occur in signaling pathways
that are implicated in the communication between stem cells
and their niche. Since WNT ligands play a crucial role for main-
taining stemness of ISCs, it is not surprising that mutations in
the APC gene are the most common cause for colorectal cancer
(CRC) initiation (Grady and Markowitz, 2002; Moser et al., 1990).
Activation of the Wnt pathway alone, however, only triggers
formation of benign adenomas, and further progression into
invasive carcinomas requires the accumulation of additional tu-
mor driver mutations (Markowitz and Bertagnolli, 2009). At these
later stages, inactivation of the transforming growth factor b
(TGF-b) signaling pathway is frequently observed (Muzny et al.,
2012). TGF-b signaling initiates growth arrest and differentiation
of intestinal stem cells (Cammareri et al., 2017; Drost et al., 2015;
Fessler et al., 2016), and cell-autonomous inhibition of the
pathway enables cancer cells to tolerate elevated TGF-b con-
centrations in the CRC microenvironment (Muñoz et al., 2006;
Takaku et al., 1998; Tauriello et al., 2018).
3D organoid culture systems derived from the intestine are
powerful tools for modeling CRC (Drost and Clevers, 2018).
While growth of organoids derived from healthy, wild-type (WT)
donors are dependent on a growth factor cocktail that mimics
the signaling environment of the intestinal stem cell niche, orga-
noids established from CRC biopsies typically lose their depen-
dency on WNT agonists, TGF-b antagonists, and EGF ligands
(Figure 1A). These findings support the concept that tumor cells
become gradually independent of niche signals during cancer
progression and make organoids a valuable tool for studying
these signaling pathways in human tissues in a physiologically
relevant setting (Drost et al., 2015; Fujii et al., 2016; Matano
et al., 2015).
Genome-wide CRISPR screens are routinely performed in
human immortalized cell lines using pooled lentiviral sgRNA
libraries (Gilbert et al., 2014; Parnas et al., 2015; Shalem et al.,
2014; Wang et al., 2014). Technical limitations, however, make
pooled screening analysis inherently noisy, and an approxi-
mately 500-fold library saturation is crucial for robust statistical
analysis of sgRNA distributions (Canver et al., 2018; Joung
et al., 2017). The resulting requirement of extensive cell numbers
has hampered the application of pooled library CRISPR
screening in 3D organoid cultures, and to our knowledge, only
targeted screens for up to 192 genes have been reported so
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Figure 1. CRISPR Screening in Organoids with Pooled sgRNA Libraries
(A) Signaling pathways relevant for hSI organoid expansion, with supplemented growth factors (bold) and genes recurrently mutated in CRC (italic).
(B) hSI organoids cultured in full, Wnt selection, or TGF-b selectionmedium. Organoids were transduced with Cas9 and sgRNAs targeting APC or SMAD4. Insets
show magnification of the boxed area. Scale bars 100 mm.
(C) Experimental outline for lentiviral organoid transduction (upper left), traditional pooledCRISPR screening (lower left), and pooledCRISPR screening with single
organoid analysis (right). See STAR Methods for details.
(legend continued on next page)
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far (Planas-Paz et al., 2019). Here, we established a method for
genome-scale CRISPR screening in human small intestinal
(hSI) organoids and applied it to genetically dissect the TGF-b
tumor suppressor pathway.
RESULTS
Establishment of Genome-Scale CRISPR Screening in
Organoids
To assess feasibility and to set up conditions for genome-wide
CRISPR screening in hSI organoids, we utilized a robust assay
for the Wnt pathway, where withdrawal of WNT3A and RSPO1
from the media enables selection of mutations in negative
pathway regulators (Figure 1B). In a pilot screen, we applied a
focused lentiviral library of 1,698 sgRNAs targeting 283 potential
tumor suppressor genes (TSGs; Table S1). Transducing the li-
brary in a single organoid cell suspension of 7 3 106 cells with
a MOI of 0.15 was a reasonable compromise between transduc-
tion efficiency and organoid survival (Figures S1A–S1C) and al-
lowed us to identify the negative Wnt-regulators AXIN1 and
APC as hits with an FDR < 1% (Figures S1D and S1E; Table
S1). However, while these results suggest that organoids can
be robustly screened with targeted CRISPR libraries, we experi-
enced that manual handling of 3D organoids makes it infeasible
to obtain and transduce the cell numbers required for genome-
scale screening. In addition, we observed that organoids estab-
lished from single cells are growing at very heterogeneous rates,
leading to a considerable distortion in sgRNA representation and
hence to accessory noise in sequencing analysis. To address
these challenges, we devised a screening approach where
sgRNA representation is not assessed in bulk genomic DNA
but captured in individual organoids (Figure 1C). Since organoids
are grown clonally from single cells, this approach entirely
eliminates noise generated from heterogenous growth rates. In
addition, it enables direct identification of false-positive hits
that originate from passenger sgRNAs co-integrated with func-
tional sgRNAs, drastically reducing the number of genes for la-
bor-intensive arrayed rescreening.
To test this method, we first transduced the genome-wide
Brunello CRISPR library targeting 19,114 genes with each of 4
sgRNAs into an organoid single cell suspension of 7 3 106 cells
and evaluated sgRNA representation by bulk genomic DNA
sequencing at day 2 and day 15 after growth under permissive
conditions (Doench et al., 2016). We observed a near complete
library representation at day 2, which was significantly reduced
at day 15 (Figures 1D, 1E, and S1F). As expected, within the
group of 1,168 drop-out genes, essential processes such as
translation and ribosomal biogenesis were significantly enriched,
and 385 genes overlapped with core-essential genes in cancer
cell lines (Figures 1F, 1G, and S1G). We next performed the
Wnt pathway screen, where we transferred transduced organo-
ids into Wnt selection conditions. Sporadically outgrowing orga-
noids were then individually isolated, sgRNA integrations were
amplified with barcoded primers, and deep sequencing with
subsequent demultiplexing was used to assign sgRNAs to indi-
vidual clones. A customized processing function was further-
more applied to discern clonally integrated sgRNA reads from
background reads, which presumably originated from DNA
traces in Matrigel co-isolated during organoid picking (see
STAR Methods). Analysis of the integrated sgRNAs revealed
that each organoid contained an sgRNA targeting either APC
or AXIN1 (Figures S2A and S2E; Table S2), demonstrating that
our approach enables robust identification of functional sgRNAs
from genome-wide CRISPR libraries. To our surprise, we
observed that in addition to the functional sgRNA, 4 passenger
sgRNAs on average were co-integrated per organoid (Figures
S2A and S2E; Table S2). Since organoids grew clonally from
single cells that were transduced at a MOI of 0.15, these data
suggest heterogenous infection within the organoid single cell
suspension.
Mutations in APC Open Additional Routes in hSI
Organoids to Acquire Resistance to TGF-b
Functional analysis of CRC organoids revealed that lines not
mutated in known TGF-b core pathway components are often
resistant to TGF-b-mediated growth inhibition (Figure S2C) (Fujii
et al., 2016), suggesting that mechanisms of TGF-b resistance in
CRC are not yet fully understood. We therefore adapted our
screening approach to a TGF-b selection assay, where removal
of the TGF-b inhibitor and addition of the TGF-b1 ligand in the
medium drives intestinal organoids into cell death (Figure 1B)
(Drost et al., 2015). After transducing the genome-wide CRISPR
library, cells were transferred into TGF-b selection conditions,
and barcoded sgRNA amplicon sequencing was used to assign
sgRNA integrations to individual organoids. Analysis of sgRNA
integrations, however, revealed that the vast majority of TGF-b
resistant organoids contained sgRNAs targeting known TGF-b
pathway components, and only 4% of clones contained sgRNAs
exclusively targeting genes without a known link to TGF-b
signaling (Figure 2A; Table S2).
According to genetic models of stepwise CRC progression,
mutations in the TGF-b pathway are late events and usually
occur in adenoma cells, in which the Wnt pathway is constitu-
tively activated via loss-of-function mutations in APC (Fearon
and Vogelstein, 1990; Muzny et al., 2012). We therefore
reasoned that mutations in these tumor suppressors might rely
on synergistic interaction with APC mutations to confer resis-
tance to TGF-b and conducted a screen in engineered APC
mutant (APCKO) hSI organoids (Figures 2B and S2B), which
compared to WT organoids showed major differences in tran-
scriptional TGF-b response (Figures 2C and 2D). Supporting
our hypothesis of increased plasticity, we found that in the
(D) Bar plots showing undetected sgRNAs (less than 10 reads) after lentiviral transduction of the library. The number above the bars represents the percentage of
undetectable sgRNAs from the whole library.
(E) Cumulative distribution function (CDF) of all sgRNAs after transduction in hSI organoids. The shift in the 15-day curve represents depletion of a subset of
sgRNAs.
(F) Enriched GO terms among genes with depleted sgRNAs shown in (E).
(G) Venn diagram comparing depleted genes in (E) with essential genes identified in cancer cell lines (Hart et al., 2015).
See also Figure S1 and Table S1.
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APCKO background, 35% of organoid clones that were resistant
to TGF-b did not contain sgRNAs targeting known TGF-b core-
pathway components (Figure 2E; Table S2). When we next per-
formed the TGF-b screen in organoids with an addition mutation
in the tumor suppressor TP53, we observed that cellular plas-
ticity was further enhanced, as organoids were occasionally
Figure 2. Single Organoid Sequencing Analysis Allows Genome-wide CRISPR-Cas9 Screening in Human Organoids
(A) Left: Dot plot showing Z-scores of sgRNAs integrated in individually recovered hSI-WT organoids from TGF-b screening. Data points for organoids with
sgRNAs targeting the TGF-b core pathway are divided into passenger sgRNAs (blue) and functional sgRNAs (green). A violin plot summarizes all functional control
sgRNAs targeting TGFBR1/2, and overlap with the violin plot was used as additional criteria to identify reads as integrated sgRNAs. Magnification shows
organoids with sgRNAs not targeting known components of the TGF-b pathway (remaining colors). Right: Bar plots summarizing results of the WT screens. See
STAR Methods for details.
(B) Confirmation of CRISPR-Cas9 generated APC mutations in hSI organoids by western blot analysis (cropped) and deep sequencing.
(C) Comparison of the transcriptional response to TGF-b in WT (orange) and APCKO hSI organoids (blue). Transcriptional changes were assessed by RNA-seq.
Bars show upregulated (LFC > 1) and downregulated genes (LFC < 1). Shared genes are labeled in gray.
(D) Enriched GO terms among TGF-b-induced genes in hSI-WT and hSI-APCKO organoids.
(E) Dot plot showing results from TGF-b screening in hSI-APCKO organoids, see (C) for explanation. n = 2 screening replicates.
See also Figure S2 and Table S2.
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Figure 3. Validation of sgRNAs that Cause Resistance to TGF-b-Mediated Growth Inhibition in hSI Organoids
(A) hSI-WT (left) and hSI-APCKO (right) organoids were transduced with the indicated sgRNAs identified in the WT screen and grown in TGF-b-selection-medium.
(B) Quantification of organoid outgrowth efficiency of hSI-APCKO organoids in TGF-b-selection medium. Data are shown as percentage of sgTGFBR2 outgrowth
efficiency. Ctrl = non-targeting sgRNA. n = 3 experiments. *p < 0.05, **p < 0.005, ***p < 0.001, Student’s t test compared to control.
(C) hSI-APCKO organoids transduced with indicated sgRNAs and expanded in TGF-b-selection medium over 3 passages.
(legend continued on next page)
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outgrowing in the non-transduced control. Nevertheless, 19% of
transduced organoids growing under TGF-b selection contained
sgRNAs against TGF-b receptors, suggesting that functional hits
can also be identified under less restrictive selection conditions
(Figure S2D; Table S2).
Identification of Screening Hits that Confer Resistance
to TGF-b in hSI Organoids
To distinguish functional hits from passenger sgRNA integra-
tions, we performed an arrayed rescreen. We first confirmed
that sgRNAs targeting the known TGF-b components TGFBR1,
TGFBR2, SMAD3, and SMAD4 were sufficient to confer resis-
tance to TGF-b treatment inWT hSI organoids (Figure 3A), allow-
ing us to dismiss all sgRNAs co-integrated in these clones for
rescreening. From the screen in the WT background, we then
confirmed FAM122A as a functional hit (Figure 3A), and from
the screen in APCKO organoids, we identified the two SWI/SNF
components ARID1A and SMARCA4 and the genes CNIH4,
KEAP1, and NBAS as functional hits (Figures 3A and 3B). Orga-
noids mutant for ARID1A, SMARCA4, KEAP1, and CNIH4 could
also be expanded under TGF-b selection over prolonged periods
(Figure 3C; >4 weeks tested), and with the exception of KEAP1
all hits could be validated by alternative sgRNAs (Figure S3A).
In contrast to mutations in known TGF-b core components,
which also induced resistance to TGF-b treatment inWT organo-
ids, we found that mutations in ARID1A, SMARCA4, CNIH4,
KEAP1, and NBAS only confer TGF-b resistance in combination
with mutant APC. We already observed occasional outgrowth of
non-transduced organoids under TGF-b selection in the APCKO/
TP53KO screen and therefore included only sgRNAs that repeat-
edly occurred in independent clones for arrayed rescreening.
With this approach we identified an additional component of
the SWI/SNF complex, namelyARID2, as a functional hit (Figures
3A–3C and S3A).
In summary, we identified ten genes that confer resistance to
TGF-b-mediated growth inhibition in intestinal organoids when
mutated, including known TGF-b pathway components and
genes that have previously not been linked to TGF-b signaling
(Table S2). Of note, when we performed a traditional genome-
wide CRISPR screen in APCKO organoids with bulk sgRNA
sequencing, we only identified TGFBR2 as a hit (Figure S3B;
Table S1), confirming enhanced accuracy and robustness of
the single organoid analysis approach for pooled library
screening in 3D culture systems.
The SWI/SNF Components ARID1A, SMARCA4, and
ARID2 Are Tumor Driver Genes in CRC
Most gastrointestinal cancers in humans develop in the colon,
prompting us to test if genes identified in the hSI organoid screen
also confer resistance to TGF-b-mediated growth restriction
when mutated in colon organoids. We found that sgRNAs
targeting FAM122A, CNIH4, NBAS, and the SWI/SNF subunits
ARID1A and SMARCA4 enabled APCKO colon organoids to
grow under TGF-b selection (Figures S3C–S3E). To next assess
if these genes also play a role in cancer progression in patients,
we used cBioportal to profile mutation frequencies across 969
CRC samples (Cerami et al., 2012; Gao et al., 2013; Giannakis
et al., 2016; Muzny et al., 2012; Seshagiri et al., 2012). Notably,
the group of SWI/SNF subunits (ARID1A,ARID2, andSMARCA4)
wasmutated in 18%of CRCpatients, which is comparable to the
mutation rate of TGF-b core-pathway components (Figure 3D).
In addition, they all scored as high-confidence CRC driver genes
when analyzed by the 20/20+ tumor driver prediction tool (Fig-
ure S3F) and showed strong tendencies for mutual exclusivity
to SMAD4 (Figure S3G). In line with these data, mutatingARID1A
and SMARCA4 in human APCKO/P53KO/KRASG12V intestinal or-
ganoids, or Arid2 in murine KrasG12D/ApcKO intestinal organoids,
enhanced formation of tumor nodules after xenotransplantation
(Figure S3H and S3I) (Takeda et al., 2019).
To next explore if perturbation of SWI/SNF subunits confers a
growth advantage to adenomas exclusively in a TGF-b-rich envi-
ronment, we performed an in vitro competition assaywhere SWI/
SNF mutant and SWI/SNF-WT APCKO organoids were mixed in
equal amounts and grown with and without the TGF-b selection,
respectively. Deep sequencing of the respective WT and KO
alleles confirmed that only in a TGF-b-rich environment do
SWI/SNF mutant organoids have a significant growth advantage
over SWI/SNF-WT organoids (Figures 3E and S3J).
Inactivation of ARID1A and SMARCA4 Modulates
Transcriptional Response to TGF-b
We next investigated how mutations in SWI/SNF components
could trigger resistance to TGF-b. In response to TGF-b1 bind-
ing, TGF-b receptors phosphorylate SMAD2/3, which subse-
quently form a stable heterodimer with SMAD4 that translocates
into the nucleus and regulates target gene transcription (Dennler
et al., 1998; Shi and Massagué, 2003). We therefore used
SMAD2 phosphorylation as a readout to assess whether muta-
tions in the SWI/SNF componentsARID1A and SMARCA4 atten-
uate the transduction of the signal from the TGF-b receptor to the
SMAD complex. While we did not observe SMAD2 phosphoryla-
tion after TGF-b treatment in APCKO/TGFBR2KO organoids), in-
duction of phosphorylation in APCKO/ARID1AKO and APCKO/
SMARCA4KO organoids was comparable toWT andAPCKO con-
trols (Figure 4A), demonstrating that signal transduction up-
stream of the SMAD transcription factors remains functional.
To next examine if the activated SMAD complex is still able to
translocate into the nucleus and regulate target gene transcrip-
tion, we performed RNA-seq analysis in organoids of the
different genotypes before and after TGF-b treatment. Of the
1,571 differentially expressed genes in the APCKO background
(>2-fold, p < 0.05; Figures 4B and 4C), 443 were dependent on
ARID1A or SMARCA4 (Figures 4B and 4C). Together, these
data suggest that the TGF-b-SMAD-signaling cascade is still
functional in SWI/SNF mutant organoids, but the transcriptional
response of TGF-b-target genes is widely attenuated.
(D) Mutation frequencies of genes identified in the screen in CRC patients. Data from 3 CRC sequencing studies with a total of 969 samples were included
(Giannakis et al., 2016; Muzny et al., 2012; Seshagiri et al., 2012).
(E) Plots showing results from growth competition between ARID1AWT versus ARID1AKO and SMARCA4WT versus SMARCA4KO organoids. n = 3 experiments.
Student’s t test. Error bars represent SD.
Insets show magnification of the boxed area. All scale bars are 100 mm, error bars represent SD. See also Figure S3.
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SWI/SNF-Dependent Chromatin Remodeling Is
Required for Correct TGF-b Target Gene Regulation
We next aimed to unravel the underlying mechanisms of the
attenuated TGF-b target gene response. Notably, mutations in
SWI/SNF lead to striking changes in gene expression in hSI orga-
noids and CRC tumors (Figures S4A and S4B). We therefore
assessed whether inactivating ARID1A or SMARCA4 in APCKO
organoids already leads to alterations in chromatin accessibility
prior to TGF-b treatment. Performing ATAC-seq, we observed
8,819 and 7,777 sites with altered accessibility upon ARID1A
or SMARCA4 mutation, respectively (Figures 4D and S4C).
When we specifically looked at changes in chromatin accessi-
bility in 443 SWI/SNF-dependent TGF-b target genes, we found
61 sites with reduced accessibility (Figures 4D and S4D; Table
S3). Thus, in a subset of TGF-b target genes, such as CPLX2,
SWI/SNF perturbation might alter the chromatin conformation
already prior to TGF-b pathway activation, thereby hindering
proper induction of target genes (Figure 4D).
It has previously been demonstrated that SMARCA4 physi-
cally interacts with SMAD2/3, suggesting that upon recruitment
to TGF-b target genes the SW/SNF complex could modulate
transcriptional regulation through remodeling of nearby chro-
matin (Ross et al., 2006; Xi et al., 2008). We therefore next
compared ATAC-seq profiles of organoids before and after
TGF-b treatment. In APCKO organoids, we found broad alter-
ations in chromatin accessibility across the genome after treat-
ment, which were completely absent in ARID1A or SMARCA4
mutant organoids (Figure 4E). When we looked at the 443 SWI/
SNF-dependent TGF-b target genes, we found that in 146 genes,
such as HEPHL1, TGF-b-induced chromatin changes were
abolished in SWI/SNF-deficient organoids, which could explain
alterations in gene expression (Figures 4E and S4D). Hence, to
induce a complete transcriptional response upon TGF-b treat-
ment that results in growth inhibition in hSI organoids, SWI/
SNF-dependent chromatin remodeling seems to be required.
Changes in chromatin accessibility upon SWI/SNF inactiva-
tion could attenuate TGF-b target gene response by altering
DNA binding specificities of SMAD complexes. We therefore
applied CUT&RUN, a method that maps protein binding on
the genome, to analyze SMAD3 binding. As SMAD3 is already
present in the nucleus without TGF-b pathway activation (Fig-
ure S4E) (Liu et al., 2016), we first compared SMAD3 binding
between APCKO, APCKO/ARID1AKO, and APCKO/SMARCA4KO
organoids prior to treatment. Our analysis revealed that
SMAD3 binding was largely altered across the genome, with
only 24.5% and 23.4% of SMAD3 binding sites in APCKO orga-
noids being conserved in the ARID1A and SMARCA4 mutant
background, respectively (Figure S4F). Similarly, only a small
fraction of the 3,739 TGF-b-induced SMAD3 binding sites
in APCKO organoids remained conserved in ARID1A and
SMARCA4 mutant organoids (1.1% and 1.7%) (Figure S4G),
whereas chromatin accessibility generally remained unaltered
at these sites after TGF-b (Figure S4H).
DISCUSSION
Here we established an approach for genome-wide CRISPR
screening in hSI organoids. We screened for resistance mecha-
nisms to the tumor-suppressive effects of TGF-b and identified
several components of the SWI/SNF chromatin remodeling
complex. Further molecular analysis led us to suggest a model
where SWI/SNF modulates TGF-b target gene response via
different mechanisms. While SWI/SNF could be required to
prime some TGF-b target genes for transcriptional regulation,
other target genes might require SWI/SNF-chromatin remodel-
ing for pathway activation (Figure 4F). In addition, it is also
conceivable that the broad transcriptomic changes upon SWI/
SNF perturbation affect expression of SMAD cofactors, thereby
indirectly altering TGF-b target gene regulation (Feng and Der-
ynck, 2005; Massagué et al., 2005). The here-presented
screening method would be broadly applicable to various orga-
noid models and selection assays and could therefore open new
avenues for genetically dissecting human disease mechanisms
in physiologically relevant model systems.
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APCKO/ARID1AKO, and APCKO/SMARCA4KO organoids, with (+) or without () TGF-b-treatment. Bottom right: ATAC-seq analysis of CPLX2 (D) or HEPHL1 (E)
with a gray box indicating changed chromatin accessibility in the mutant backgrounds. Error bars represent SD.
(F) Model of how SWI/SNF inactivation causes resistance to TGF-b-mediated growth repression.
See also Figure S4 and Table S3.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti-human-cytokeratin (CAM5.2) Becton Dickinson CAT# 345779;
RRID: AB_10687527
Rabbit monoclonal anti-phospho-SMAD2 (138D4) Cell Signaling Technology CAT# 3108;
RRID: AB_490941
Rabbit monoclonal anti-SMAD2 (D43B4) Cell Signaling Technology CAT# 5339;
RRID: AB_10626777
Rabbit monoclonal anti-BETA-ACTIN (13E5) Cell Signaling Technology CAT# 5125;
RRID: AB_2223172
Rabbit monoclonal anti-GAPDH (14C10) Cell Signaling Technology CAT# 2118;
RRID: AB_10693448
Rabbit polyclonal anti-APC Sigma-Aldrich CAT# SAB4501438;
RRID: AB_10762093
Rabbit polyclonal anti-SMAD3 Abcam CAT# ab28379;
RRID: AB_2192903
Goat polyclonal anti-ECAD RnD systems CAT# AF748;
RRID: AB_355568
Donkey anti-Rabbit IgG Thermo CAT# A10042;
RRID: AB_2534017
Donkey anti-Goat IgG Thermo CAT# A11055;
RRID: AB_2534102
Chemicals, Peptides, and Recombinant Proteins
Advanced DMEM/F-12 Thermo CAT# 12634028
HEPES Thermo CAT# 15630-056
GlutaMax Thermo CAT# 35050-038
Penicillin-Streptomycin Thermo CAT# 15140-122
EGF Peprotech CAT# AF-100-15
N-Acetylcysteine Sigma-Aldrich CAT# A9165
Gastrin Tocris CAT# 3006
Nicotinamide Sigma-Aldrich CAT# N0636
B-27 Supplement Thermo CAT# 17504044
A83-01 TGFBR inhibitor Tocris CAT# 2939
Nutlin-3 Cayman Chemicals CAT# 548472-68-0
ROCK inhibitor Y-27632 Sigma-Aldrich CAT# Y0503
Matrigel Corning CAT# 354230
Critical Commercial Assays
Lenti-X qRT-PCR Titration Kit Takara CAT# 631235
Deposited Data
CRISPR screen This study GEO: GSE145185
RNA-seq data This study GEO: GSE145185
ATAC-seq data This study GEO: GSE145185
CUT&RUN-seq data This study GEO: GSE145185
Experimental Models: Cell Lines
Human: HEK293T ATCC RRID: CVCL_0063
Experimental Models: Organisms/Strains
Mouse: NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ Charles River RRID: ARC:NSG
HUB043 HUB platform HUB-02-B2-043
(Continued on next page)
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Prof.
Dr. Gerald Schwank (schwank@pharma.uzh.ch). All unique reagents generated in this study are available from the Lead Contact
with a completed Materials Transfer Agreement.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human material for organoid culture
Human intestinal biopsies were obtained from the University Hospital Z€urich. Written informed consent was obtained from all pa-
tients, and the study was approved by the Cantonal Ethics committee of the north-western part of Switzerland and the Cantonal
Ethics Committee of the Canton Z€urich. CRC organoid lines were obtained from the Hubrecht Organoid Technology (HUB) platform
(https://www.hub4organoids.eu).
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
HUB055 HUB platform HUB-02-B2-055
HUB044 HUB platform HUB-02-B2-044
HUB087 HUB platform HUB-02-B2-087
Oligonucleotides
See Table S4 for primers for sgRNA detection This study N/A
See Table S4 for primers for quantification of
editing events
This study N/A




lentiCRISPR v2 plasmid Sanjana et al., 2014 RRID: Addgene_52961
Human sgRNA library Brunello Doench et al., 2016 RRID: Addgene_73179
TSG-sub-library This study N/A
Software and Algorithms
GraphPad Prism software v8.30 GraphPad https://www.graphpad.com/scientific-software/prism/;
RRID:SCR_002798
ZEN Digital Imaging for Light Microscopy Zeiss https://www.zeiss.com/microscopy/en_us/products/
microscope-software/zen.html; RRID:SCR_013672
FlowJo software v10.2 FlowJo, LLC https://www.flowjo.com/solutions/flowjo;
RRID:SCR_008520
RStudio RStudio https://www.rstudio.com/; RRID: SCR_000432
Edge R Bioconductor package Robinson et al., 2010 http://bioconductor.org/packages/release/bioc/html/
edgeR.html; RRID:SCR_012802
MAGeCK v0.5.4 Li et al., 2014 https://sourceforge.net/projects/mageck/
MACS2 v2.1.2 Zhang et al., 2008 https://github.com/taoliu/MACS; RRID:SCR_013291)






IGV 2.5.2 Broad Institute https://software.broadinstitute.org/software/igv/;
RRID:SCR_011793
HOMER v4.10.4 Heinz et al., 2010 http://homer.ucsd.edu/homer/; RRID:SCR_010881
CRISPRScreen processing function This study https://github.com/cherkaos/
CRISPRScreenProcessing
CLC Genomics Workbench 8 QIAGEN http://digitalinsights.qiagen.com/products-overview/
discovery-insights-portfolio/analysis-and-visualization/
qiagen-clc-genomics-workbench/
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Mice
All animal experiments were performed in accordance with protocols approved by the Kantonales Veterinaramt Zurich in compliance
with all relevant ethical regulations. Male NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were obtained from Charles River Labora-
tories and used for transplantation studies without any other interventions. Adult NSG mice were housed in a pathogen-free animal
facility in cages with up to five animals at the Institute of Molecular Health Sciences at ETH Zurich and kept in a temperature- and
humidity-controlled room on a 12-h light–dark cycle.
METHOD DETAILS
Human Small Intestinal and human Colon Organoids
Normal human small intestinal and colon tissues were isolated from resected segments derived from patients. Isolation of intestinal
crypts was described previously (Sato et al., 2011). In short, the biopsies were placed in complete chelating solution CCS (5.6 mM
Na2HPO4, 8 mM KH2PO4, 96.2 mM NaCl, 1.6 mM KCl, 43.4 mM sucrose, and 54.9 mM D-sorbitol). Dithiothreitol and EDTA were
added just before use to a final concentration of 0.5 mM and 2 mM, respectively. The biopsies were then incubated for 20-45 min
at 4C on a rocking plate. After incubation, tubes were shaken vigorously to liberate the crypts. Tissue fragments were allowed to
settle for 1 min, and supernatant containing crypts was transferred to a new tube. One volume of FBS (Sigma) was added and crypts
were spun down at 150 g for 3 min. Next, the crypts were washed twice with Advanced DMEM/F12 (GIBCO) supplemented with
10 mMHEPES, 1x Glutamax, 1% Penicillin/Streptomycin and spun down for 5 min at 150 g. Crypts were subsequently resuspended
in ice-cold Matrigel GFR (Corning) and plated in 20 ml drops on pre-warmed standard tissue culture plates, polymerized for 10 min at
37C and covered with human intestinal organoid medium containing 10 mM Y-27632 RhoKinase inhibitor (Abmole) and 100 mg/mL
Primocin (Invivogen). Culture medium of Human Intestinal Organoids contained Advanced DMEM/F12 supplemented with 10 mM
HEPES, 1x Glutamax, 1% Penicillin/Streptomycin, 1x N2, 1x B27 (all from GIBCO), 1.25 mM N-acetylcysteine (Sigma), 50%
WNT3A-conditioned medium (CM), 20% RSPO1-CM 20%, 10% NOGGIN-CM (all CM produced in-house), 10 mM Nicotinamide
(Sigma), 50 ng/mL human EGF (Peprotech), 10 nM Gastrin (Tocris Bioscience), 0.5 mMTGF-b type I receptor inhibitor A83-01 (Tocris
Bioscience) and 10 mM p38-inhibitor SB202190 (Sigma). The same medium was used for small intestinal- and colon organoids. For
mutant APC selection, organoids were cultured in medium lackingWNT3A-CM and RSPO1-CM. For mutant TP53 selection, organo-
ids were cultured in the presence of 10 mMNutlin-3a (Sigma). Organoid lines were constantly tested for mycoplasma contamination
and resulted negative.
Targeted gene knock-out in organoids using lentiviral transduction
Organoids were expanded as described before, harvested in ice-cold Advanced DMEM/F12 and pelleted by centrifugation.
Organoids were dissociated to the single cell level by resuspending the cells in pre-warmed TrypLE Express Enzyme 1x (GIBCO)
and incubating at 37C with occasional vigorous vortexing for 8-12 min. The dissociation process was observed under the
microscope and the enzymatic reaction was stopped using DMEM supplemented with 10% FBS and 1% Penicillin/Streptomycin.
The cells were pelleted and taken up in a transduction mix containing Advanced DMEM/F12 supplemented with 10 mM HEPES,
1x Glutamax, 1x Penicillin / Streptomycin, 4 ug/mL Polybrene (Merck), 10 mM RhoKinase inhibitor and concentrated lentivirus.
The transduction mix was seeded in a cell culture plate and centrifuged for 1 h at 600 g at room temperature and incubated for
3 h at 37C. Finally, the cells were harvested, seeded in Matrigel and overlaid with expansion medium containing 10 mM RhoKinase
inhibitor. To select for organoids transduced with a Puromycin cassette, medium containing 1-1.5 mg / ml Puromycin (Invivogen) was
added 3 days post-transduction. To select for CRISPR/Cas9-mediated knock out events, organoids were cultured for 7 days for
depletion of gene products and subsequently passaged into selection medium. Successful knock-out of the target genes was
validated with deep sequencing. Target-specific primers were designed flanking the predicted sgRNA cut-sites and containing
primer binding sites for Illumina TruSeq Deep sequencing primers. The respective amplicons were purified and sequenced on an
Illumina MiSeq System, aiming at a minimum of 5,000 reads per locus. Sequencing reads were processed with CLC Genomics
Workbench 8 and mapping of the reads and quantification of editing events was performed with CRISPResso V1.0.11 (Pinello
et al., 2016).
Lentivirus Production
For virus production, HEK293T cells (ATCC, RRID: CVCL_0063) were seeded in T175 cell culture flasks in DMEM (GIBCO) supple-
mented with 10% FBS and 1% Penicillin/Streptomycin and grown to 70% confluency. Cells were PEI-transfected with the following
transfection mix: 10.4 mg psPAX2-Plasmid, 3.5 mg pMD2.G, 13.8 mg LentiCRISPRV2 in a volume of 1000 ml Opti-MEM (GIBCO) in
tube 1. In a second tube, 138 ml 1mg/mL Polyethylenimine (Polysciences) was mixed with 862 ml Opti-MEM. Both tubes were equil-
ibrated to room temperature for 5 min, mixed, and incubated 20 min at room temperature. The cells were transduced with 1600 ml of
the transduction mix. After 24 h, the medium was replaced with Opti-MEM. After 48 h, the supernatant containing the lentivirus was
harvested, filtered through 0.45 mm syringe filters (Sarstedt) and concentrated by centrifugation at 20,000 g for 2 h. Titration of lenti-
virus was performed using the Lenti-X qRT-PCR Titration Kit (Takara). Lentivirus was stored at 80C. Plasmids psPAX2 (Addgene
#12260) and pMD2.G (Addgene #12559) were gifts from Didier Trono, Plasmid LentiCRISPRV2 (Addgene #52961) was a gift from
Feng Zhang.
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Pooled traditional CRISPR screens
Sublibrary screen
For the pooled traditional CRISPR screens, human small intestinal organoids were expanded, harvested, and dissociated into
approximately 7 3 106 single cells per replicate. Cells were transduced with the lentiviral tumor suppressor gene sub-library, with
a physical titer of 2,563 109 viral particles/mL, in a reaction volume of 16ml. For each of the three replicates perWnt pathway screen,
lentiviral transduction was performed separately. Transduced organoids were seeded in Matrigel and grown in expansion medium.
Three days after transduction, organoids fully recovered and approximately 63 105 cells were harvested as a library baseline control,
separately to medium lacking WNT3A-CM and RSPO1-CM for the Wnt-screen. On day 21 after transduction, surviving organoids
were harvested from five 6-well cell culture plates and genomic DNA was extracted. Next, the integrated sgRNAs were amplified
for deep sequencing using primer pair sgRNA_region_for and sgRNA_region_rev. The amplicons were processed with the Illumina
TruSeq Nano DNA Library Prep Kit and paired-end sequencing was performed on a HiSeq2500 system. Reads were processed with
CLC Genomics Workbench 8 and subsequent read mapping and analysis was done using MAGeCK V0.5.4.
Genome-wide screen
For the pooled traditional genome-wide CRISPR screens, human small intestinal organoids were expanded, harvested, and
dissociated into approximately 7 3 106 single cells per replicate. Cells were transduced with the lentiviral Brunello genome-wide
library with a physical titer of 2,563 109 viral particles/mL, in a reaction volume of 16ml. For each of the screening replicates, lentiviral
transduction was performed separately. A single screen was performed for the Wnt pathway, and two TGF-b screening replicates
were performed per genotype (hSI-WT, hSI-APCKO and hSI-APCKO/TP53KO), resulting in a total of six TGF-b screening replicates.
Transduced organoids were seeded in Matrigel and grown in expansion medium for one week. Organoids were then passaged to
TGF-b-selection medium, and 10 days after start of selection, outgrowing organoids from both replicates were harvested separately
and integrated sgRNAs were sequenced. In parallel, the same number of organoid cells were transduced with the genome-wide
library and grown in full medium for 2 days, before organoids were harvested and sgRNAs were sequenced as control. Differential
sgRNA representation between the two TGF-b selection condition replicates and the control condition was analyzed using
MAGeCK 0.5.4.
Library coverage and depletion assay
To assess library coverage, 73 106 organoid cells were transduced similar to the genome-wide organoid screening approach. At day
2 after transduction, organoids were harvested. gDNA was isolated using the QIAamp DNA Blood Midi Kit (QIAGEN) and eluted in
water. sgRNA sequences were amplified from 110 mg gDNA following the suggested protocol with slight modifications (Sanson
et al., 2018), using Herculase II Fusion DNA Polymerase (Agilent) and 7.5 ug of gDNA per 100 ul PCR reaction. Deep sequencing
was performed with Illumina MiSeq V3 reagents, aiming at a minimum of 100 reads per sgRNA. To test depletion of sgRNAs against
essential genes, hSI organoids were again transduced similar to the genome-wide organoid screening approach, and cultured for
15 days, which included one passaging step. At day 15, a total of 150 mg gDNAwas isolated and used for PCR. TheMAGeCK pipeline
for the identification of essential genes was used for differential analysis of mapped reads 2 days and 15 days after library transduc-
tion. sgRNAs with a LFC < 0.5 and p < 0.05 were considered as depleted.
Genome-wide screening using single organoid sequencing analysis
For genome-wide screening, 7x 106 organoid cells were transducedwith the Brunello sgRNA library with a physical titer of 2,563 109
viral particles/mL, in a reaction volume of 16 ml, and cultured in expansion medium. On Day 7 post-transduction, organoids were
passaged into selection conditions. Of note, occasionally organoids broke in parts and continued to grow as independent organoids,
explaining why some organoids had identical combinations of passenger sgRNA integrations (in Table S2 these organoids were clas-
sified into clonal events). During the passaging procedure, all wells were kept separate to avoid complete reshuffle of transduced
cells. After 1-2 weeks, cystic organoids were picked, washed in ice-cold PBS and stored in PCR-reaction tubes. Extraction of
genomic DNA was performed by adding 5 ml lysis mix to each single organoid, which contained 50% v/v DirectPCR Lysis Reagent
(Viagen), 1mg/mL proteinase K (QIAGEN), and incubated for 1 h at 55C and 45min at 85C. For the subsequent PCR reaction, 2 ml of
sample was added. Reaction was performed using NEB High-Fidelity Master mix (New England Biolabs), with 26 cycles and the bar-
coded target-specific primers listed (Table S4). The resulting bands were gel-purified using the NucleoSpin Gel and PCRClean up Kit
(Macherey-Nagel). The purified products were combined in batches of 30, each containing unique barcodes. The batches were
concentrated using the PCR Clean up Kit and sequenced similar to the pooled screen process. The resulting reads were processed
and demultiplexed using CLC Genomics Workbench 8 and reads were mapped and quantified using MAGeCK V.0.5.4.
Library saturation in screens
In our genome-wide screens, we used a lentiviral titer that transduced 15% of the 8 mio. organoid cells (Figure S1A). Deep
sequencing of organoids selected in the Wnt- and TGF-b assays revealed that transduced organoids had on average 4-5 sgRNAs
integrated (Figure S2E), possibly because lentiviral transduction is limited to a subpopulation of cells in organoids. In our screens,
we therefore obtained 4 3 106 sgRNA integrations. The genome-wide library used in our study contained 76,441 sgRNAs, and is
therefore represented approximately at a 50-fold coverage.
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Candidate validation and outgrowth quantification
Organoids were Puromycin selected after transduction with the desired Cas9 and sgRNA construct, and densely grown selected
organoids were then harvested from four 20ml Matrigel drops. Organoids were thoroughly dissociated using TrypLE and a flame-
polished Pasteur pipette and subsequently filtered through a 40 mmcell strainer. Single cells were then plated in 20 ml Matrigel drops.
Only cystic organoids in a single plane of focus were counted as outgrowing organoids, and a total of eight drops were quantified.
Organoid outgrowth was reported in relation to sgTGFBR2 transduced organoids, since TGFBR2 is one of the most potent and most
upstream TGF-b signaling mediators.
Organoid Transplantations
Human intestinal organoids were transplanted subcutaneously into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG, obtained from Charles
River Laboratories, RRID: ARC:NSG). Per flank, 6 3 20 ml drops of organoids were injected in 100 ml PBS:Matrigel (1:1). Organoids
were collected in cold Advanced DMEM/F12 to wash off the Matrigel before they were mechanically dissociated into smaller cell
clusters and injected. Per genotype, a total of 4 animals was injected. Mice were controlled bi-weekly and sacrificed 9 weeks
post transplantation.
Histology
Mice were sacrificed with CO2 before s.c. tumors were extracted, dehydrated and embedded in paraffin. Paraffin sections of sub-
cutaneous tumors were stained with Hematoxylin/Eosin as well as with anti-Human Cytokeratin (1:100, BD Biosciences, Cam5.2,
RRID: AB_10687527) to label human cells.
Whole mount immunofluorescence
Per sample, 3 3 20 ml Matrigel droplets with organoids were harvested and Matrigel was removed using Cell Recovery Solution
(Corning). After washing in PBS, organoids were fixed 30 min at RT in 4% PFA. Following fixation, organoids were washed 3 x in
PBS before permeabilization and blocking solution was applied (10% normal donkey serum; 0.5% Triton X-100 in PBS) in 1.5 mL
Eppendorf tubes overnight at 4C on a rocker (as for all subsequent incubations). Samples were incubated with the following primary
antibodies: SMAD3 (1:100, Abcam ab28379, RRID: AB_2192903), E-Cadherin (1:500, R&D Systems, AF748, RRID: AB_355568).
After three washes in PBS – 0.5% Triton X-100 (PBS-T), organoids were incubated with secondary antibodies (Donkey anti-Rabbit
568, ThermoFisher A-10042, RRID: AB_2534017 andDonkey anti-Goat 488, ThermoFisher A-11055, RRID: AB_2534102; both 1:400)
and counterstained with DAPI. Organoids were washed 3 x in PBS-T andmounted with ProLong Gold (Invitrogen, P36934). Confocal
Images were taken with a Leica SP8 microscope at 40X magnification.
Western Blotting
Per sample, 8 3 20 ml Matrigel droplets with organoids were harvested and Matrigel was removed using Cell Recovery Solution
(Corning). Samples were lysed in RIPA buffer (50mMTris-HCl pH 8.0, 150mMNaCl, 0.1%SDS, 0.5%Na-Deoxycholate, 1% IGEPAL
CA-630) supplemented with PhosSTOP phosphatase inhibitors and cOmplete protease inhibitor cocktail (both Roche). Protein was
quantified using standard BCA protein assay (ThermoScientific). Protein was separated on 10% SDS-PAGE gels and subsequently
transferred to nitrocellulose membranes (GE Healthcare) in Towbin buffer. Membranes were blocked in 5% Bovine Serum Albumin
(PAN Biotech) and incubated overnight in primary antibodies phospho-SMAD2 (1:2000; Cell Signaling Technology 138D4, RRID:
AB_490941), SMAD2 (1:3000; Cell Signaling Technology D43B4, RRID: AB_10626777); b-Actin (1:5000; Cell Signaling Technology
13E5, RRID: AB_2223172) and GAPDH (1:5000; Cell Signaling Technology 14C10, RRID: AB_10693448). HRP-conjugated second-
ary antibody was used for detection. Protein bands were visualized with Clarity ECL Western Substrate (Bio-Rad) and a Fujifilm LAS
4000 imager.
For APC blotting, samples were loaded on 4%–15% precast polyacrylamide gels (Bio-Rad) and transferred overnight to PVDF
(Bio-Rad) membranes in Towbin buffer (plus 0.025% SDS). Membranes were blocked in 5% skim-milk (Rapilait) and subsequently
probed with primary antibody against APC (1:750, SAB4501438 Sigma, RRID: AB_10762093).
Generation of TSG sub library, library amplification, and cloning of individual sgRNAs
For the pooled screen, we first established a list of most frequently mutated tumor suppressor genes across various epithelial
cancers, including cancer of the colon, liver, lung, pancreas, prostate, kidney, ovaries, breast, bladder, thyroid, stomach, melanoma
and endometrium. We used the MutSig2CV analytical branch of the Firebrowse pipeline to collect the 30 most mutated genes from
each cancer, and cross checked with TUSONExplorer to select genes with a tendency toward features common in tumor suppressor
genes (Davoli et al., 2013). In cases with no tendency toward oncogenic signature or tumor suppressive signature, genes were
included anyways. In the next step, we used the sgRNA-Designer platform of the Broad Institute to design 6 sgRNAs per genes, re-
sulting in 1,698 sgRNAs against 283 genes (https://portals.broadinstitute.org/gpp/public/analysis-tools/sgRNA-design; Doench
et al., 2016). Using the protocol from Shalem et al., we adapted the sgRNA design for subsequent cloning into the LentiCRISPRv2
backbone (Shalem et al., 2014). The Brunello library was ordered from Addgene (#73179). For sufficient coverage and equal sgRNA
distribution across the library, the vector including the sgRNAwas electroporated into Endura Electrocompetent E. coli (Lucigen) and
plated on ten 10 cm LB agar plates (TSG) and four 24,5 cm bio assay dishes. Bacterial colonies were scraped off and plasmid DNA
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was isolated using the Nucleo BondMidi X-Plus Kit (Macherey-Nagel). Individual sgRNAs were cloned using the same protocols, but
only single bacterial clones were picked for plasmid DNA isolation.
Fluorescence-activated cell sorting (FACS)
Human small intestinal organoids were transduced with a lentivirus carrying Cas9-GFP and sgRNA against APC and analyzed 7 days
after transduction. Organoids were dissociated with TrypLE Express Enzym (GIBCO), and resuspended in FACS buffer (1% FBS,
5 mM EDTA and 10 mM RhoKinase inhibitor in PBS). Sytox Red (Invitrogen) was added for the exclusion of dead cells. Data were
acquired on a BD LSR Fortessa cell analyzer (Becton Dickinson) and were further analyzed using FlowJo software (FlowJo 10.2).
In all experiments, a minimum of 50,000 cells were analyzed, if not stated otherwise. For gating, forward versus side scatter
(FSC-A versus SSC-A) gating was used to identify cells of interest. Doublets were excluded using the forward scatter height versus
forward scatter area density plot (FSC-H versus FSC-A). Live cells were gated based on Sytox-Red-negative staining. Live-gated
cells were further used to quantify the percentage of eGFP negative and eGFP positive populations.
RNA-Sequencing
Library preparation
For RNA extraction, 8 3 20 ml Matrigel droplets with organoids were harvested and organoid pellets were lysed in RLT buffer. RNA
was isolated using the RNeasy Kit (QIAGEN) according to the manufacturer’s instructions. The quality of the isolated RNA was
determined with a Qubit (1.0) Fluorometer (Life Technologies) and a Bioanalyzer 2100 (Agilent). Only those samples with a
260 nm/280 nm ratio between 1.8–2.1 and a 28S/18S ratio within 1.5–2 were further processed. The TruSeq RNA Sample Prep
Kit v2 (Illumina) was used in the succeeding steps. Briefly, total RNA samples (100-1000 ng) were poly-A enriched and then
reverse-transcribed into double-stranded cDNA. The cDNA samples were fragmented, end-repaired and polyadenylated before liga-
tion of TruSeq adapters containing the index for multiplexing. Fragments containing TruSeq adapters on both ends were selectively
enriched with PCR. The quality and quantity of the enriched libraries were validated using Qubit (1.0) Fluorometer and the Caliper
GX LabChip GX (Caliper Life Sciences). The libraries were normalized to 10nM in Tris-Cl 10 mM, pH8.5 with 0.1% Tween 20. The
TruSeq PE Cluster Kit HS4000 or TruSeq SR Cluster Kit HS4000 (Illumina) was used for cluster generation using 10 pM of pooled
normalized libraries on the cBOT. Sequencing was performed on the Illumina HiSeq2000 single end 100 bp using the TruSeq
SBS Kit HS4000 (Illumina, Inc, California, USA).
Data analysis
Readswere quality-checkedwith FastQC. Sequencing adapters were removedwith Trimmomatic and readswere hard-trimmed by 5
bases at the 30 end (Bolger et al., 2014). Successively, reads at least 20 bases long, and with an overall average phred quality score
greater than 10were aligned to the reference genome and transcriptome ofHomo sapiens (FASTA andGTF files, respectively, down-
loaded fromGRCh38) with STAR v2.5.1 with default settings for single end reads (Dobin et al., 2013). Distribution of the reads across
genomic isoform expression was quantified using the R package GenomicRanges from Bioconductor Version 3.0 (Lawrence et al.,
2013). Differentially expressed genes (DE) were identified using the R package edgeR from Bioconductor Version 3.0 (Robinson
et al., 2010).
A gene is marked as DE if it possesses the following characteristics: 1) at least 10 counts in at least half of the samples in one
group, 2) p < 0.05. and 3) log2 ratio > = 1.
ATAC-seq
Library preparation
Library preparation was carried out with minor modifications as described elsewhere (Buenrostro et al., 2013). For ATAC-Seq with
hSI organoids, organoids were dissociated into single cells and 50,000 cells were lysed in 50 ml cold Lysis buffer (10 mM Tris-HCl,
pH 7.4, 10 mM NaCl, 3 mMMgCl2, 0.1% IGEPAL CA-630). After centrifugation at 500 g for 10 min at 4C, cells were resuspended in
1X transposition mix (Illumina; 25 ml Tagment DNA Buffer, 2.5 ml Tagment DNA Enzyme, 22.5 ml ddH2O) and incubated for 30 min at
37C on a shaker at 300 rpm. Immediately after the transposition reaction, DNA was purified using the QIAgen MinElute PCR
Purification Kit according to the manufacturer’s instructions. Library was amplified with Nextera Sequencing primers in NEBNext
Q5 Hot Start HiFi 2X PCR master mix for 5 cycles. To remove large DNA fragments, the PCR reaction was incubated with 0.55X
AMPure XP beads (Beckman Coulter) and the unbound supernatant was subsequently purified with QIAgen MinElute coloumns.
Again, DNA was amplified with Nextera Sequencing primers in NEBNext Q5 Hot Start HiFi 2X PCR master mix for 9 cycles. Finally,
to remove primers and small DNA fragments, PCR reaction was bead-purified with 1.8X AMPure XP beads. Bound DNAwas eluted in
20 ml EB buffer and quantified and visualized for quality control with a 2200 TapeStation System (Agilent).
Data processing
Raw sequencing reads were filtered for low-quality after adaptor removal and aligned on GRCh38 using Bowtie2 with default map-
ping parameters (Langmead and Salzberg, 2012). PCR duplicates were removed using Picard. The mapped reads of all replicates
were merged for each condition prior to peak calling. Peaks were called on each sample using MACS2 with ‘‘–nomodel–shift
100–extsize 200,’’ to obtain a consensus peak set for each sample (Zhang et al., 2008). The peak set was used to build a count
matrix using the aligned reads for all samples and their replicates. Differential peaks between sample groups were identified using
edgeR. For this, the count matrix was filtered for peaks with low coverage across all samples based on minimum read count of 10 for
each sample. The remaining counts were normalized using the total library size as well as edgeR’s TMM derived normalization
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factors. Between two sample groups, only regions with a log fold change above > 0.5 and an FDR value < 0.05 were considered as
differentially accessible for further analysis. The peaks were annotated using HOMER (Heinz et al., 2010).
CUT&RUN - chromatin profiling
Library preparation
Cut and Run targeted chromatin profiling was performed as described by Skene et al. (Skene et al., 2018). In brief, for each condition,
200.000 single cells were harvested from human small intestinal organoids. After two washes, cells were bound to 10 ml of Conca-
navalin A-coated beads (Bangs Laboratories, cat. no. BP531), diluted in 1ml of binding buffer and rotated 10 min at RT. Cells were
cleared on a magnetic rack and beads were resuspended in 50 ml antibody solution. The antibody anti-SMAD3 (1:50, abcam28379;
RRID: AB_2192903) was used, and incubated on a rotator overnight at 4C. Beads were cleared on a magnetic rack and washed in
digitonin buffer before resuspension in 50 ml of digitonin buffer with 700 ng/ml pA-MNase (kindly received from Kopf/Henikoff Lab), in
order to bind the fusion protein to the antibody. After 1h rotating at 4C, beads were cleared on amagnetic rack andwashed twice. To
activateMNase activity, beads were resuspended in 150 ml digitonin buffer and chilled down to 0C before 3 ml of 100mMCaCl2were
added for 30 min at 0C. Reaction was stopped by adding 150 ml of 2X Stop buffer and tubes were incubated for 10 min at 37C to
release chromatin. After centrifugation for 5 min at 4C at 16 000 g, tubes were placed on a magnetic rack in order to remove beads.
The supernatant was collected and purified using the NucleoSpin PCR clean up kit (Macherey-Nagel, cat. no. 740609.250). DNAwas
stored at 20C before Illumina library preparation.
Sequencing libraries were made using the NEBNext Ultra II DNA Library Prep Kit for Illumina (E7645) according to the manufac-
turer’s description. Clean up steps between the reactions (End repair/Adaptor ligation and PCR) were performed by using AMPure XP
beads (Beckmann Coutler, A63881). Quality control of amplified libraries was carried out on an Agilent 2200 TapeStation System and
Paired-End Sequencing was performed on an Illumina NovaSeq Machine.
Data processing
Quality control of fastq files was done using FastQC before analysis was started. After adaptor and PCR duplicate removal reads
were mapped to the human genome (GRCh38) using Bowtie2 with options ‘‘–local–very-sensitive-local–no-unal–no-mixed–no-
discordant–phred33 -I 10 -X 700.’’ Differential peaks in SMAD3 binding (Treated versus Untreated) were called using MACS2,
applying the following parameters: ‘‘–nomodal–extsize 160.’’ Profiles were displayed using IGV version 2.5.3. The peaks were anno-
tated using HOMER.
To consider a peak as overlapping between the ATAC-Seq dataset and SMAD3 CUT&RUN dataset, the center of the ATAC-Seq
peak should lie between the start and end coordinates of a SMAD3 peak.
Identification of sgRNAs in TGF-b screens
To identify sgRNAs for follow up experiments, we have devised a processing function in R (RCore Team, 2017). Because of the nature
of our screening approach, in which we do not compare treated and non-treated pools, we decided to use the information of abun-
dant positive controls to identify functional sgRNAs. We first selected positive control clones with high read counts for sgRNAs
targeting known positive regulators (APC, AXIN, TGFBR1/2). For these control clones, we identified integrated sgRNAs, removed
background sgRNAs reads, and applied the learned pattern to analyze integrated sgRNAs in clones. Processing function steps:
1. Manual identification of positive control organoid clones with high read counts for sgRNAs targeting known positive regulators.
2. For all integrations, Z-scores of the reads are calculated to make read count values comparable to each other.
3. For each control clone, the processing function ranks sgRNAs from high to low and identifies largest drop in read count (fold
change) between two consecutive sgRNAs.
4. The smallest read count drop (fold change) among control clones is selected as minimum threshold for integrated sgRNAs.
5. Identification of sgRNAs in non-control clones: only clones with sgRNAs read count drop bigger than the threshold are selected
by processing function.
6. Generation of summary table containing control clones and non-control clones (candidates) with identified integrated sgRNAs.
Data available in Table S2.
In-silico tumor driver analysis
Prediction of driver genes was performed using 20/20+ version 1.0.3 with the in-built trained classifier and parameters
‘‘NUMSIMULATIONS: 100000’’ and ‘‘NUMITER: 10’’ (Tokheim et al., 2016). For the mutations, we combined the MAF files for colo-
rectal adenocarcinoma from TCGA (Giannakis et al., 2016; Seshagiri et al., 2012).
In order to test for mutual exclusivity between the screening hits and members of TGF-b pathway, we used TiMEx version 0.99.0
(Constantinescu et al., 2016).We focused only on TCGA samples aswe used bothmutations and copy number alterations in the input
binary alterations matrix, and reported the resulting significant (q < 0.1) interactions.
Assessment of trends in DE genes between the transcriptomes of tumor samples and organoids
We used the R package ‘TCGABiolinks’ (Colaprico et al., 2016) to access RNaseq data and mutation profiles for the colorectal
adenocarcinoma (COAD) dataset. We collected data from patients with no mutations in the TGF-b core pathway (Smads, receptors)
and defined three subgroups: 1) The control group not possessing mutations in SWI/SNF components, 2) the first SWI/SNF-per-
turbed group consisting of patients with amutation in SMARCA4, and 3) the second SWI/SNF-perturbed group consisting of patients
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with a mutation in ARID1A. We performed a differential expression analysis between the control and each perturbed group using the
R package ‘edgeR’. To compare the transcriptional changes, we looked at the overlap of the LFC-ranked lists as a function of the top
n genes. To assess significance of the overlap, we used a permutation test. We randomly permuted the ranks of the lists and again
computed the overlap as a function of the top n genes as before. The permutation was performed 10,000 times. We considered as
significant an overlap above the 5%-significance level, i.e., an overlap larger than 95% of all permutations.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are presented as mean of N biological replicates and with standard deviation (SD). Exact value of n is stated in the figure leg-
ends. No strategy for experiment randomization was used, and no blinding was used in the study. No samples or animals were
excluded from the analysis.
Significance of data was analyzed using the two-tailed, unpaired Student’s t test function in Prism (GraphPad) for the comparison
of two groups.
TheMAGeCKpackage (https://sourceforge.net/projects/mageck/, v.0.5.4) was used to analyze pooled CRISPR screen outcomes.
Total read counts were chosen as normalization method, and p < 0.05 was chosen as a cut off for significantly enriched or
depleted genes.
DATA AND CODE AVAILABILITY
Results of sequencing of pooled screens are provided in Table S1. Results of single organoid sequencing are provided in Table S2.
Results of chromatin accessibility profiling and profiling of transcription factor binding are provided in Table S3.
The datasets generated during this study are available at Gene Expression Omnibus (GEO). Original DNA-sequencing data for
Figures 1 and 2, source RNA sequencing data for Figures 2 and 4, ATAC-seq and CUT&RUN data for Figure 4 are deposited under
accession number GEO: GSE145185.
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